Cerdablan

Pharmacotherapeutic group: drugs used in nicotine dependence, ATC code: N07BA04 The use of Cytisinicline allows for a gradual reduction of nicotine dependence by relieving withdrawal symptoms. The active ingredient of Cytisinicline is a plant alkaloid cytisinicline (found, among others, in seeds of golden chain, genus Laburnum ), with a chemical structure similar to nicotine. It has an effect on acetylcholine nicotinic receptors. The action of cytisinicline is similar to that of nicotine, but in general weaker. Cytisinicline competes with nicotine for the same receptors and gradually displaces nicotine due to its stronger binding. It has lower ability to stimulate nicotinic receptors, mainly α 4 β 2 subtype (it is their partial agonist) and less than nicotine passes into the central nervous system. It is hypothesized that in the central nervous system cytisinicline acts on the mechanism involved in nicotine dependence and on the release of neurotransmitters. It prevents nicotine‑dependent full activation of the mesolimbic dopamine system and moderately increases level of dopamine in the brain, what alleviates the central symptoms of nicotine withdrawal. In the peripheral nervous system, cytisinicline stimulates and then affects the autonomic ganglia of the nervous system, causes a reflex stimulation of breathing and secretion of catecholamines from the core part of the adrenal gland, raises blood pressure and prevents peripheral symptoms of nicotine withdrawal.